- Home
- NMRA vs ACV Comparison
NMRA vs ACV Comparison
Compare NMRA & ACV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NMRA
- ACV
- Stock Information
- Founded
- NMRA 2019
- ACV 2015
- Country
- NMRA United States
- ACV United States
- Employees
- NMRA N/A
- ACV N/A
- Industry
- NMRA
- ACV Finance/Investors Services
- Sector
- NMRA
- ACV Finance
- Exchange
- NMRA Nasdaq
- ACV Nasdaq
- Market Cap
- NMRA 291.5M
- ACV 253.6M
- IPO Year
- NMRA 2023
- ACV N/A
- Fundamental
- Price
- NMRA $3.01
- ACV $25.82
- Analyst Decision
- NMRA Buy
- ACV
- Analyst Count
- NMRA 8
- ACV 0
- Target Price
- NMRA $7.43
- ACV N/A
- AVG Volume (30 Days)
- NMRA 3.0M
- ACV 38.8K
- Earning Date
- NMRA 11-06-2025
- ACV 01-01-0001
- Dividend Yield
- NMRA N/A
- ACV 9.20%
- EPS Growth
- NMRA N/A
- ACV N/A
- EPS
- NMRA N/A
- ACV N/A
- Revenue
- NMRA N/A
- ACV N/A
- Revenue This Year
- NMRA N/A
- ACV N/A
- Revenue Next Year
- NMRA N/A
- ACV N/A
- P/E Ratio
- NMRA N/A
- ACV N/A
- Revenue Growth
- NMRA N/A
- ACV N/A
- 52 Week Low
- NMRA $0.61
- ACV $16.82
- 52 Week High
- NMRA $14.09
- ACV $23.74
- Technical
- Relative Strength Index (RSI)
- NMRA 75.77
- ACV 73.48
- Support Level
- NMRA $2.40
- ACV $25.28
- Resistance Level
- NMRA $3.25
- ACV $25.20
- Average True Range (ATR)
- NMRA 0.27
- ACV 0.40
- MACD
- NMRA 0.11
- ACV 0.08
- Stochastic Oscillator
- NMRA 84.76
- ACV 89.82
About NMRA Neumora Therapeutics Inc.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.
About ACV Virtus Diversified Income & Convertible Fund of Beneficial Interest
Virtus AllianzGI Diversified Income & Convertible Fund is a diversified, limited-term, closed-end management investment company. The fund's investment objective is to provide total return through a combination of current income and capital appreciation while seeking to provide downside protection against capital loss. It invests in a diversified portfolio of convertible securities, income-producing equity securities, and income-producing debt and other instruments of varying maturities, of which a majority of the managed assets are invested in convertibles.